Email this article Certolizumab pegol in treatment of Crohn's disease with perianal lesions
- Authors: Khalif IL1, Nanaeva BA1, Shapina MV1, Vardanyan AV1
-
Affiliations:
- A.N. Ryzhikh State Scientific Centre of Coloproctology Ministry of Health of Russia
- Issue: Vol 90, No 4 (2018)
- Pages: 50-54
- Section: Editorial
- URL: https://bakhtiniada.ru/0040-3660/article/view/32462
- ID: 32462
Cite item
Full Text
Abstract
Aim. To assess the effectiveness of conservative treatment of Crohn's disease (CD) with perianal lesions. Materials and methods. The study included 20 patients with CD with perianal fistulae. Prior to the start of conservative therapy, 7 patients underwent fistulae drainage with setton placement. During the study, all patients received therapy with certolizumab pegol (CP) for a year. At the time of treatment initiation and after 12 months, the CD activity index, the quality of life according to IBDQ questionnaires and the perianal Crohn's disease activity index (PCDAI) were assessed. Results. After a year of CP therapy, clinical remission was achieved in 8 (40%) patients, endoscopic remission in 7 (35%) patients, fistula closure in 6 (30%) patients. There was also a decrease in the PCDAI with the average score 3.6 points compared to 9.3 points (p˂0.05) prior to the treatment. An improvement in the quality of life of patients was also established, the average quality of life index was 182,2 points compared to 156,0 points (p˂0.05) prior to the treatment. Conclusion. This study showed that CP therapy is effective in treatment of CD with perianal lesions.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
I L Khalif
A.N. Ryzhikh State Scientific Centre of Coloproctology Ministry of Health of Russiaр мед. наук, проф., руководитель отд. по изучению воспалительных заболеваний кишечника Moscow, Russia
B A Nanaeva
A.N. Ryzhikh State Scientific Centre of Coloproctology Ministry of Health of Russia
Email: nanaeva1987@mail.ru
к.м.н., н.с. отд. по изучению воспалительных и функциональных заболеваний кишечника Moscow, Russia
M V Shapina
A.N. Ryzhikh State Scientific Centre of Coloproctology Ministry of Health of Russiaк.м.н., с.н.с. отд. по изучению воспалительных и функциональных заболеваний кишечника Moscow, Russia
A V Vardanyan
A.N. Ryzhikh State Scientific Centre of Coloproctology Ministry of Health of Russiaк.м.н., н.с. отд. хирургии ободочной кишки Moscow, Russia
References
- Felley C, Mottet C, Juillerat P, et al. Fistulizing Crohn’s disease. Digestion. 2007;76:109-12. doi: 10.1159/000111024
- Schwartz D.A, Loftus E.V. Jr, Tremaine W.J, et al. The history of fistulizing Crohn’s disease of Olmsted Country, Minnesota. Gastroenterology. 2002;122:875-80. doi: 10.1053/gast.2002.32362
- Kamm M.A, Ng S.C. Perianal fistulizing Crohn’s disease: a call to action. Clin Gastroenterol Hepatol. 2008;6:7-10. doi: 10.1016/j.cgh. 2007.10.010
- Никулина И.В., Златкина А.Р., Белоусова Е.А. и др. Оценка клинико - эпидемиологических показателей воспалительных заболеваний кишечника в Московской области. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 1997;(2):67-71
- Sandborn W, Fazio V, Feagan B, et al. AGA technical review on perianal Crohn’s disease. Gastroenterology. 2003;125(5):1508-30. doi: 10.1016/j.gastro.2003.08.025
- Neilsen O.H, Rogler G, Hahnloser D, Thomsen O.O. Diagnosis and management of fistulizing Crohn’s disease. Nat Clin Pract Gastroenterol Hepatol. 2009;6:92-106. doi: 10.1038/ncpgasthep1340
- Шелыгин Ю.А., Жарков E.E., Орлова Л.П. и др. Отдаленные результаты иссечения анальной трещины в сочетании с боковой подкожной сфинктеротомией. В кн.: Актуальные проблемы колопроктологии. Москва; 2005. С.141-2
- Judge T.A, Lichtenstein G.R. Treatment of fistulizing Crohn’s disease. Gastroenterol Clin North Аm. 2004;33:421-54. doi: 10.1016/j.gtc. 2004.03.002
- Wilkins T, Jarvis К, Patel J. Diagnosis and management of Crohn’s disease. Am Family Phys. 2011;84:1365-75.
- Thia K.T, Mahadevan U, Feagan B.G, et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn’s disease: a randomized, double - blind, placebo - controlled pilot study. Inflam Bowel Dis. 2009;15:17-24. doi: 10.1002/ibd.20608
- Person D.C, May G.R, Fick G.H, Sutherland L.R. Azathioprine and 6-mercaptopurine in Crohn’s disease. A meta - analysis. Ann Inter Med. 1995;123:132-42. doi: 10.7326/0003-4819-123-2-199507150-00009
- Behm B.W, Bickston S.J. Tumor necrosis factor - alpha antibody for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD006893. doi: 10.1002/14651858.CD006893
- Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease meta - analysis of placebo - controlled trials. Clin Gastroenterol Hepatol. 2008;6:644-53. doi: 10.1016/j.cgh.2008.03.014
- Schreiber S, Lawrance I, Thomson O, et al. Randomised clinical trial: certolizumab pegol for fistulas in Crohn’s disease - subgroup results from a placebo - controlled study. Aliment Pharmacol Ther. 2011 Jan;33(2):185-93. doi: 10.1111/j.1365-2036.2010.04509.x
- Vavricka S, Schoepfer A, Bansky G, et al. Efficacy and safety of Certolizumab pegol in an unselected Crohn’s disease opulation: 26-week data of the FACTS II survey. Inflamm Bowel Dis. 2011;17(7): 1530-9. doi: 10.1002/ibd.21521
- Lennard-Jons J. Classification of inflammatory bowel disease. Scand J Gastroenerol. 2007;42:576-82.
- Pikarsky A, Gervaz Р, Wexner S. Perianal Crohn disease: a new scoring system tevaluate and predict outcome of surgical intervention. Arch Surg. 2002;137:774-8. doi: 10.1001/archsurg.137.7.774
Supplementary files
